Maverick Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Maverick Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,082	Closed	-$1.48M	–	416
2023 Q1	$1.48M	Buy	3,082 +2,447	+385%	+$1.15M	0.04%	103
2022 Q4	$267K	Buy	+635	New	+$256K	0.01%	315
2021 Q3	–	Sell	-273	Closed	-$176K	–	651
2021 Q2	$176K	Buy	273 +50	+22%	+$30.4K	﹤0.01%	500
2021 Q1	$127K	Sell	223 -193	-46%	-$114K	﹤0.01%	552
2020 Q4	$243K	Buy	+416	New	+$237K	﹤0.01%	492
2020 Q3	–	Sell	-915	Closed	-$413K	–	580
2020 Q2	$413K	Buy	+915	New	+$404K	0.01%	462

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Maverick Capital's BIO Position: Q2 2023 in Review

Maverick Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 3,082 shares — an estimated $1.48M sold.

Maverick Capital first reported a position in BIO in Q2 2020 and held it in 6 quarters. The position peaked at $1.48M in Q1 2023. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

Maverick Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
Maverick Capital sold 3,082 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $1.48M.
Maverick Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2020 and held it in 6 quarters.
Maverick Capital's Bio-Rad Laboratories Class A position peaked at $1.48M in Q1 2023.
469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Maverick Capital's 13F filing for Q2 2023, filed 14 Aug 2023.